- 著者
- 三島 江津子 岡戸 洋 加藤 さおり 櫛原 秀之 黒田 純子 榊原 隆志 首代 みどり 鈴木 厚志 松岡 加恵 宮坂 朋恵 渡辺 法男 横田 学 板倉 由縁 鈴木 照美 斉藤 寛子
- 出版者
- 一般社団法人日本医療薬学会
- 雑誌
- 医療薬学 = Japanese journal of pharmaceutical health care and sciences (ISSN:1346342X)
- 巻号頁・発行日
- vol.35, no.6, pp.403-408, 2009-06-10
- 参考文献数
- 11
- 被引用文献数
- 1
When pharmacists provide drug guidance to in-patients,they are often asked about health foods such patients are regularly taking in expectation of anti-cancer effects.However,pharmacists cannot always answer these questions based on scientific evidence.<br>To further evaluate the efficacy of health foods for this purpose,we did a survey of the literature concerning 5 frequently used health foods said to have anticancer effects using the PubMed and Ichushi search services,obtaining 1,300 papers from the former and 1,142 papers from the latter.However among them,we could not find any providing data from randomized controlled trials and thus there was no clear scientific evidence,though some of the papers noted an improvement in the quality of life of patients.<br>In conclusion,when pharmacists provide guidance on health foods to patients and their families,it is important for them to collect detailed information and evaluate them on a scientific basis.
- 著者
- 三島 江津子 岡戸 洋 加藤 さおり 櫛原 秀之 黒田 純子 榊原 隆志 首代 みどり 鈴木 厚志 松岡 加恵 宮坂 朋恵 渡辺 法男 横田 学 板倉 由縁 鈴木 照美 斉藤 寛子
- 出版者
- 一般社団法人日本医療薬学会
- 雑誌
- 医療薬学 (ISSN:1346342X)
- 巻号頁・発行日
- vol.35, no.6, pp.403-408, 2009 (Released:2010-08-19)
- 参考文献数
- 11
- 被引用文献数
- 1 1
When pharmacists provide drug guidance to in-patients,they are often asked about health foods such patients are regularly taking in expectation of anti-cancer effects.However,pharmacists cannot always answer these questions based on scientific evidence.To further evaluate the efficacy of health foods for this purpose,we did a survey of the literature concerning 5 frequently used health foods said to have anticancer effects using the PubMed and Ichushi search services,obtaining 1,300 papers from the former and 1,142 papers from the latter.However among them,we could not find any providing data from randomized controlled trials and thus there was no clear scientific evidence,though some of the papers noted an improvement in the quality of life of patients.In conclusion,when pharmacists provide guidance on health foods to patients and their families,it is important for them to collect detailed information and evaluate them on a scientific basis.
1 0 0 0 OA がん患者が訴える痛みの表現と鎮痛薬の効果
- 著者
- 西田 希久代 遠山 幸男 久野 久美 平野 茂樹 出口 裕子 松田 唯子 渡辺 貴志 山関 知恵 板倉 由縁 斎藤 寛子 長谷川 高明
- 出版者
- 日本緩和医療学会
- 雑誌
- Palliative Care Research (ISSN:18805302)
- 巻号頁・発行日
- vol.4, no.1, pp.207-213, 2009 (Released:2009-05-15)
- 参考文献数
- 12
がん患者は複雑な痛みをさまざまな言葉で表現する. こうした表現から薬剤の効果を推測することができ, 適切な疼痛緩和へつながると考え, 本調査を行った. がん性疼痛のある患者164名から, 529語(108種類)の痛みの表現を収集し, 使用頻度の高い痛みの表現に対するオピオイドおよび非ステロイド性消炎鎮痛薬(NSAIDs)の効果を評価した. その結果, 「重い」や「どーん」という表現はオピオイドが効きやすく, 「しびれ」や「ぴりぴり」はオピオイドが効きにくい表現であることが推測された. 医療従事者は, 患者の言葉に耳を傾け, 患者の痛みを把握することが重要であり,このことが良好な疼痛緩和につながると考える.Palliat Care Res 2009; 4(1): 207-213
- 著者
- 杉本 智哉 近藤 有 一木 万奈美 荒川 裕貴 間瀬 広樹 牛膓 沙織 佐久間 昌基 小山 佐知子 大島 有美子 宮崎 雅之 築山 郁人 佐藤 由美子 久田 達也 板倉 由縁 山田 清文
- 出版者
- 一般社団法人日本医療薬学会
- 雑誌
- 医療薬学 (ISSN:1346342X)
- 巻号頁・発行日
- vol.44, no.9, pp.441-448, 2018-09-10 (Released:2019-09-10)
- 参考文献数
- 26
- 被引用文献数
- 1
The objective of this study was to evaluate the cost-effectiveness of pegfilgrastim (Peg-G) and daily filgrastim (Fil-G) for the primary prophylaxis against febrile neutropenia (FN) in patients with non-Hodgkin lymphoma (NHL) who received cyclophosphamide, vincristine, doxorubicin and prednisolone (CHOP) therapy. We developed a decision analytical model reflecting the clinical processes of NHL patients who received first CHOP therapy. The probabilities at each clinical endpoint were obtained from published sources. To estimate the costs and duration of FN treatment, we analyzed the medical records of NHL patients in hospitals participating in this study. The costs of Peg-G and Fil-G were calculated according to the National Health Insurance drug price list. We assessed an incremental cost-effectiveness ratio (ICER) for a single dose of Peg-G versus 11-days of Fil-G from the perspective of health insurance payers. The sensitivity and robustness of this model were validated by the tornado-diagram and Monte Carlo Method. The costs associated with primary prophylaxis with a single dose of Peg-G and 11-days of Fil-G were 109,628 JPY and 109,243 JPY, respectively. The quality adjusted life years (QALYs) associated with the two strategies were 0.0339 QALYs and 0.0337 QALYs, respectively. The ICER for the Peg-G versus Fil-G was 2,788,571 JPY per QALY. The tornado-diagram revealed that the main influential factors included the cost of Peg-G, number of Fil-G doses, and cost of Fil-G. Monte Carlo simulation revealed an 18.3% probability that Peg-G was cost-effective compared with Fil-G. A single dose of Peg-G was cost-effective compared with 11-days of Fil-G.
- 著者
- 佐々木 俊則 大島 有美子 三島 江津子 伴 晶子 桂川 健司 永松 秀紹 吉岡 祐貴 築山 郁人 久田 達也 板倉 由縁 水谷 三浩
- 出版者
- 公益社団法人 日本薬学会
- 雑誌
- YAKUGAKU ZASSHI (ISSN:00316903)
- 巻号頁・発行日
- vol.136, no.7, pp.1023-1029, 2016 (Released:2016-07-01)
- 参考文献数
- 15
It is often necessary to modify the dose or schedule of eribulin mesilate (Eri) because of adverse events. Therefore, we retrospectively investigated the optimal approach for Eri dose adjustment and/or dosage interval adjustment. Patients who received Eri at the institutions affiliated with the Division of Oncology of the Aichi Prefectural Society of Hospital Pharmacists between July 2011 and November 2013 were enrolled in this study. We compared the group that underwent dose reduction without changes to their dosage interval (dose reduction group) with the group that had a change in their dosage interval (dose-interval prolongation group). The primary end-point was time to treatment failure (TTF), and the secondary end-points were overall survival (OS), overall response rate (ORR), clinical benefit rate (CBR), and adverse events. The TTF and OS of the dose reduction group were approximately two times longer than those of the dose-interval prolongation group. In addition, the dose reduction group had significantly improved ORR and CBR, which together indicate an antitumor effect (p=0.013 and 0.002, respectively). Although peripheral neuropathy occurred significantly more frequently in the patients in the dose reduction group (p=0.026), it was grade 1 and controllable in most of the cases. There were no differences in the occurrence of other adverse effects between the two groups. Therefore, we suggest that dose reduction with maintenance of the dosage interval is the preferred treatment approach in cases where Eri dose or schedule modification is necessary.